

Demystifying the Science Behind Targeted Treatments for Haematological Cancers

Virtual study day

Wednesday 3 February 2021

Aims:

The aim of this course, spread over two mornings, is to provide learners with a good, general understanding of the biology, genetics and behaviours of many haematological cancers. Educator, Dr Elaine Vickers, will also provide an up-to-date overview of modern systemic treatment approaches given to people with various haematological cancers. This includes CAR T cell therapy and other targeted approaches that have come through clinical trials in recent years.

Dr Vickers' goal is to explain the science that underpins each treatment. She also hopes to provide learners with a broad understanding of why treatments work well for some patients but not for others.

Elaine's presentations are full of colourful and enlightening illustrations to help learners make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a limited understanding of cell biology are able to understand.

Audience:

This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with haematological cancers, and to junior doctors.

Cost:

£50 per day

Register:

www.royalmarsden.nhs.uk/studydays

Get in touch:

Conferenceteam@rmh.nhs.uk

020 7808 2921

Follow us:



Programme- Day 2:

This morning Elaine turns her attention to various forms of haematological cancer and explains the science behind the treatment approaches developed for each type. Elaine finishes the morning by explaining the concepts that underpin CAR T cell therapy, and its growing importance as a treatment for some cancers.

10:00 Welcome and Introductions

10:10 Session 1—Targeted treatments for chronic lymphocytic leukaemia, non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukaemia (ALL)

- Description of CD20-targeted antibody therapies
- BiTEs, bi-specifics and conjugated antibodies
- B cell receptor signalling pathway inhibitors (targeting BTK, PI3K δ , CD79B)
- Bcl-2 Inhibitors

10:45 Live Q&A

10:55 Break/Sponsor Exhibition

11:00 Session 2—Treatments for myeloma, acute myeloid leukaemia, Hodgkin lymphoma and chronic myeloid leukaemia (CML)

- Treatments for multiple myeloma: proteasome inhibitors, immunomodulators, monoclonal antibodies
- Treatments for acute myeloid leukaemia; targeting IDH1/2, FLT3, smoothened, CD33, Bcl-2
- Kinase inhibitors for CML (and ALL)
- Targeting CD30 and PD-1 for Hodgkin lymphoma

11:35 Live Q&A

11:45 Break/Sponsor Exhibition

11:50 Session 3—CAR T cell therapy for ALL, NHL, Myeloma

- Overview of the process
- CAR protein design- what each bit does and why it matters
- Reasons for side effects
- Reasons for resistance
- Results so far

12:25 Live Q&A

Please note that the content will be available for 30 days after the event online.

Sponsors:

The above sponsors provided funding for the study day, but they have had no input into the programme, selection of speakers or topics.